Matsson Pär, Englund Gunilla, Ahlin Gustav, Bergström Christel A S, Norinder Ulf, Artursson Per
Pharmaceutical Screening and Informatics, Department of Pharmacy, Uppsala University, P.O. Box 580, SE-751 23 Uppsala, Sweden.
J Pharmacol Exp Ther. 2007 Oct;323(1):19-30. doi: 10.1124/jpet.107.124768. Epub 2007 Jul 6.
In this article, we explore the entire structural space of registered drugs to obtain a global model for the inhibition of the drug efflux transporter breast cancer resistance protein (BCRP; ABCG2). For this purpose, the inhibitory effect of 123 structurally diverse drugs and drug-like compounds on mitoxantrone efflux was studied in Saos-2 cells transfected with human wild-type (Arg482) BCRP. The search for BCRP inhibitors throughout the drug-like chemical space resulted in the identification of 29 previously unknown inhibitors. The frequency of BCRP inhibition was 3 times higher for compounds reported to interact with other ATP-binding cassette (ABC) transporters than for compounds without reported ABC transporter affinity. An easily interpreted computational model capable of discriminating inhibitors from noninhibitors using only two molecular descriptors, octanol-water partition coefficient at pH 7.4 and molecular polarizability, was constructed. The discriminating power of this two-descriptor model was 93% for the training set and 79% for the test set, respectively. The results were supported by a global pharmacophore model and are in agreement with a two-step mechanism for the inhibition of BCRP, where both the drug's capacity to insert into the cell membrane and to interact with the inhibitory binding site of the transporter are important.
在本文中,我们探索了已注册药物的整个结构空间,以获得抑制药物外排转运蛋白乳腺癌耐药蛋白(BCRP;ABCG2)的全局模型。为此,我们研究了123种结构各异的药物和类药物化合物对用人类野生型(Arg482)BCRP转染的Saos-2细胞中米托蒽醌外排的抑制作用。在类药物化学空间中寻找BCRP抑制剂,结果鉴定出29种以前未知的抑制剂。据报道与其他ATP结合盒(ABC)转运蛋白相互作用的化合物对BCRP的抑制频率,是没有报道ABC转运蛋白亲和力的化合物的3倍。构建了一个易于解释的计算模型,该模型仅使用两个分子描述符,即pH 7.4时的正辛醇-水分配系数和分子极化率,就能区分抑制剂和非抑制剂。这个双描述符模型对训练集的区分能力分别为93%,对测试集的区分能力为79%。这些结果得到了全局药效团模型的支持,并且与抑制BCRP的两步机制一致,在该机制中,药物插入细胞膜的能力和与转运蛋白抑制性结合位点相互作用的能力都很重要。